Astellas Pharma (ALPMY)
(Delayed Data from OTC)
$10.57 USD
+0.23 (2.22%)
Updated Aug 1, 2025 03:59 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALPMY 10.57 +0.23(2.22%)
Will ALPMY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALPMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALPMY
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year?
Is Alpha Cognition Inc. (ACOG) Outperforming Other Medical Stocks This Year?
ALPMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
Here's Why Astellas Pharma (ALPMY) Is a Great 'Buy the Bottom' Stock Now
Other News for ALPMY
Astellas Pharma enters MOU with KISED for pact with Global Companies Program
Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship ...
Pfizer, Astellas say Xtandi regimen hit secondary goal in late-stage trial for prostate cancer
Pfizer's xtandi plus leuprolide improves survival in prostate cancer
Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study